Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

Exclusion Criteria

• •Is not a good candidate to receive any of the drugs administered in the study for a given disease (idelalisib, bendamustine, rituximab, ofatumumab, fludarabine, everolimus, bortezomib, or chlorambucil), according to the clinical judgment of the investigator
• •Patients with atypical immunophenotype with t(11:14) translocation or cyclin D1 over-expression (CLL patients only)
• •Had radiotherapy, radioimmunotherapy, biological therapy, chemotherapy, or treatment with an investigational product within 4-weeks prior to the baseline disease status tests
• •Had treatment with a short course of corticosteroids for symptom relief within 1-week prior to the baseline disease status tests
• •Has had an allogeneic hematopoietic stem cell transplant
• •Has known active central nervous system involvement of the malignancy
• •Is pregnant or nursing
• •Has active, serious infection requiring systemic therapy. Patients may receive prophylactic antibiotics and antiviral therapy at the discretion of the investigator
• •Has absolute neutrophil count (ANC) \< 1000/µL, unless it is related to underlying CLL, MCL or indolent NHL, the latter documented by \> 50% infiltration of bone marrow by tumor cells
• •Has platelet count \< 75000/µL, unless it is related to underlying CLL, MCL, or iNHL, the latter documented by \> 50% infiltration of bone marrow by tumor cells
• •Has serum creatinine ≥ 2.0 mg/dL
• •* For Cohort 7 only: Has creatinine clearance \< 60 mL/min
• •Has serum bilirubin ≥ 2 mg/dL (unless due to Gilbert's syndrome) for patients with iNHL or CLL; for patients with MCL, serum bilirubin ≥ 1.5 x upper limit of normal
• •Has serum aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ≥ 2 x upper limit of normal
• •Has Child-Pugh Class B or C hepatic impairment
• •Has a positive test for HIV antibodies
• •Has active hepatitis B or C (confirmed by RNA test). Patients with serologic evidence of prior exposure are eligible.
• •Prior treatment with idelalisib